Peptide Bioregulators: Khavinson Peptides and What the Evidence Shows

A distinct group within the peptide landscape goes by names such as Cortexin, Thymalin, Cardiogen, Livagen, Pinealon, Vesugen, Suprefort, Ovagen, Visoluten, Sigumir, Prostamax, Testagen, Ventfort, Pancragen, Glandokort, Cortagen, Chonluten, Thymagen, Bronchogen, Taxorest and Vilon. They are commonly called peptide bioregulators or Khavinson peptides. They are covered together here because they share a common origin, a common theoretical basis, and a common evidentiary situation — and treating them as twenty separate topics would obscure the single fact that matters most about all of them.

This guide situates Peptide Bioregulators within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

Where the bioregulators come from

This work originates with Vladimir Khavinson and colleagues, initially within Soviet military medicine and later at the St Petersburg Institute of Bioregulation and Gerontology. The program dates to the 1970s and has continued for decades — this is a sustained research effort, not a marketing invention, and it deserves to be described accurately.

The work proceeded in two generations. The first produced organ extracts — peptide preparations isolated from specific animal tissues, marketed as cytamins. Thymalin from thymus, Cortexin from cerebral cortex and Epithalamin from pineal gland are examples. These are complex mixtures, not defined single molecules.

The second generation produced synthetic short peptides, the cytogens, typically two to four amino acids long, intended to represent the active sequences. Vilon (Lys-Glu), Epitalon (Ala-Glu-Asp-Gly), Pinealon (Glu-Asp-Arg) and Cardiogen (Ala-Glu-Asp-Arg) are of this type.

The distinction matters clinically. An organ-derived extract and a defined synthetic tetrapeptide are different kinds of product with different characterization, consistency and contamination profiles, even when marketed under the same conceptual umbrella.

The bioregulator hypothesis

The underlying proposal is that each tissue produces short tissue-specific peptides that regulate gene expression within that same tissue, that this signaling declines with age, and that supplying the corresponding peptide restores normal function in the organ it came from.

Hence the naming convention, which is essentially a directory: Cardiogen for heart, Livagen and Ovagen for liver, Suprefort and Pancragen for pancreas, Visoluten for retina, Prostamax for prostate, Testagen for testis, Glandokort for adrenal, Sigumir for cartilage, Chonluten, Bronchogen and Taxorest for lung, Vesugen and Ventfort for vasculature, Cortexin and Cortagen for brain, Thymalin, Thymagen and Vilon for thymus.

Proposed mechanisms in the published work include direct interaction of short peptides with DNA and modulation of transcription. There is legitimate general science establishing that small peptides can penetrate cells and reach the nucleus, and that peptide-DNA interactions occur. The contested step is not whether short peptides can influence gene expression — it is whether these specific peptides produce the specific tissue-restorative clinical effects claimed for them.

The state of the evidence

There is a substantial published literature on these compounds. Studies report effects on immune parameters, on markers of aging, on organ function, and in some cases on mortality in elderly cohorts. Some of this work spans long follow-up periods.

The limitation is structural rather than a matter of any single study's quality. The great majority of this literature originates from the same research group and its associated institutions, is published substantially in Russian-language journals, and has seen limited independent replication by unaffiliated investigators.

Independent replication is not a bureaucratic formality. It is the mechanism by which science distinguishes a real effect from the accumulated influence of a single group's methods, assumptions and expectations. A body of work of any size that has not been reproduced outside its originating environment occupies a genuinely different evidentiary position from one that has — regardless of how many papers it contains.

Additional constraints recur across the literature: modest sample sizes, endpoints that are frequently biochemical or subjective rather than hard clinical outcomes, variable blinding and randomization, and limited accessibility of full methods to reviewers outside the language and system in which the work was produced.

None of this establishes that the compounds do nothing. It establishes that the evidence does not currently support clinical recommendation, and that is a different and more accurate statement than either dismissal or endorsement.

Epitalon is the most widely studied member and has its own guide; the same evidentiary caveats apply to it.

Regulatory status and how these are sold

None of these compounds is FDA-approved for any indication in the United States. None is an established bulk drug substance for 503A compounding.

They are typically sold as oral capsules positioned as dietary supplements, or as injectable preparations offered through overseas suppliers. The oral supplement route raises an obvious pharmacologic question that marketing rarely addresses: short peptides taken orally face digestion by gastric and intestinal proteases, and evidence that these particular peptides survive that passage intact in meaningful quantity is not established.

Products sourced from overseas suppliers carry the usual concerns about identity, purity, sterility and accurate dosing. For organ-derived extracts specifically, source material and processing introduce additional contamination considerations that a defined synthetic peptide does not.

How to handle this with patients

Patients encountering these compounds are usually well-read, often specifically interested in longevity, and frequently aware that a real research program exists behind them. Dismissing the category as fringe is both inaccurate and unpersuasive to that patient.

The accurate framing has three parts. The research program is genuine and long-running. The evidence has not been independently replicated to the standard that would justify clinical use. And these products are not approved, not compoundable, and generally sourced outside regulated supply chains.

That framing respects the patient's reading while being honest about what is known. It also identifies exactly what would change the assessment: independent replication. If unaffiliated groups reproduce these findings with adequate methods, the position should change accordingly. Our peptide formulary lists each of these agents individually with its current status.